SCHEMBL783484

SCHEMBL783484

O=C(Nc1ccc(Oc2ccnc(NC(=O)N3CCCC3)c2)c(F)c1)c1cc(-c2cnccn2)cn(-c2ccccc2)c1=O

nearest known ligand 0.56

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
AXL P30530 9/20 0.56
MET P08581 12/20 0.53
RIPK3 Q9Y572 3/20 0.51
RIPK2 O43353 2/20 0.51
RIPK1 Q13546 2/20 0.51
PTK2B Q14289 1/20 0.51
MERTK Q12866 3/20 0.49
KDR P35968 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL199864 0.80 AXL (0.61) AXLMETRIPK3RIPK2RIPK1
SCHEMBL200002 0.76 MET (0.79) AXLMETMERTKKDR
SCHEMBL4728517 0.75 MET (0.62) AXLMETKDR
SCHEMBL14019962 0.75 AXL (0.54) AXLMETKDR
SCHEMBL201059 0.75 MET (0.78) AXLMETMERTKKDR
SCHEMBL1472392 0.75 MET (0.62) AXLMETRIPK3RIPK2RIPK1
SCHEMBL4882739 0.75 KDR (0.55) AXLMETKDR
SCHEMBL1472526 0.74 AXL (0.54) AXLMETRIPK3RIPK2RIPK1
SCHEMBL4882755 0.73 MET (0.56) AXLMETMERTKKDR
SCHEMBL200073 0.73 MET (0.66) AXLMETKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1881976-B1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC (US) 2012-10-17 EP disclosed
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES KIM TAE-SEONG (US) 2012-03-22 US disclosed
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES KIM TAE-SEONG (US) 2012-03-22 US disclosed
US-8088794-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2012-01-03 US disclosed
US-8088794-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2012-01-03 US disclosed
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2011-05-19 US disclosed
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2011-05-19 US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312232-A1 Substituted amide derivatives and methods of use HGF, HGFAC, MET AXL 776/4885MET 3/4885RIPK3 3408/4885
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES HGF, HGFAC, MET AXL 855/4885MET 3/4885RIPK3 3835/4885
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET AXL 776/4885MET 3/4885RIPK3 3408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.